{"id":"W2264465777","doi":"10.3111/13696998.2016.1151432","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; McGill University; Golder Associates (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Erlotinib; Nivolumab; Docetaxel; Quality-adjusted life year; Oncology; Lung cancer; Quality of life (healthcare); Cost effectiveness; Survival analysis; Internal medicine; Cancer; Immunotherapy; Epidermal growth factor receptor; Risk analysis (engineering)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001337338,0.00009611607,0.000693582,0.0000850237,0.0000132888,0.000002303451,0.0000997529,0.00005514815,0.00005128989],"category_scores_gemma":[0.0001193586,0.00005413628,0.0001176771,0.00002307644,0.00005871821,0.00004889619,0.00000976942,0.0000508001,4.933685e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000792122,"about_ca_system_score_gemma":0.001936575,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01830122,"about_ca_topic_score_gemma":0.3750782,"domain_scores_codex":[0.9985247,0.00003584173,0.001034526,0.00009599634,0.0001953957,0.0001135494],"domain_scores_gemma":[0.9987001,0.0004787939,0.0005388386,0.0001210299,0.00006669628,0.00009457331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.008029884,0.0004004591,0.06129692,0.0001291508,0.0007106159,0.000001152422,0.001009759,0.05062151,0.0008603742,0.000111979,0.0000276606,0.8768005],"study_design_scores_gemma":[0.03040786,0.002468812,0.04774169,0.0003656011,0.000388476,0.00002455189,0.001427278,0.9121131,0.004387374,0.0002214359,0.0003201122,0.000133727],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927999,0.001880127,0.001290823,0.003370334,0.0002472989,0.0003622411,0.00003543689,7.038232e-7,0.00001311041],"genre_scores_gemma":[0.9987219,0.0006617942,0.0005178958,0.00002931142,0.00004294231,0.000008869304,0.000001270042,0.000008961973,0.000007067466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8766668,"threshold_uncertainty_score":0.988236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1385477431919973,"score_gpt":0.3627472802013817,"score_spread":0.2241995370093845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}